Title: Formulation for insulin and glucose control
United States Patent: 6,967,030
Issued: November 22, 2005
Inventors: Wright; Jonathan V. (36338 32nd S., Auburn, WA
98001); Block; Wallace E. (28 Dolores St., San Rafael, CA 94901)
Appl. No.: 342843
Filed: January 14, 2003
The formulation includes a combination of a chalcone, specifically,
methylhydroxychalcone polymer, in the amount of 6 mg to 24 mg, and chromium,
in the amount of 500 mcg to 2000 mcg. The formulation also includes a
plurality of vitamins and nutrients, vitamins B6, C, E and K
including green tea polyphenols and other nutrients.
Description of the Invention
This invention relates generally to insulin and glucose control therapy
and more specifically concerns a formulation for enhancing insulin
BACKGROUND OF THE INVENTION
Insulin control therapy in various forms is well known. Its primary use
has been relative to treatment of type 2 diabetes. Type 2 diabetes is a
common disorder characterized typically by several metabolic abnormalities,
including insulin resistance and insulin deficiency. These abnormalities
result in hyperglycemia, which can in turn result in cardiovascular
morbidity and mortality. Glucose control will delay the onset and retard the
progression of microvascular and possibly macrovascular disease in those
individuals having type 2 diabetes.
Various techniques and treatments are known for glucose control. In one type
of treatment, lifestyle changes are used to improve insulin sensitivity.
These changes include weight loss, dietary change and exercise. As the
disease progresses oral insulin secretagogues and insulin sensitizers are
used, either separately or together, in order to maintain proper glucose
levels. In the final stages of the disease, due to its progressive nature,
including the progressive decline in pancreatic beta-cell function, insulin
supplementation is usually required to achieve the desired glycemic goals.
This treatment requires highly motivated patients. Many individuals with
type 2 diabetes, however, cannot use insulin supplementation, including the
elderly and those with co-morbid conditions. For these individuals, as well
as other individuals with particular medical or physical limitations,
insulin administration treatments are precluded.
For certain individuals, insulin is used along with oral antidiabetic
medications to normalize glycemia. This has been an effective alternative to
direct injection of insulin. This type of therapy is often effective for
those individuals who show some responsiveness to oral anti-diabetic
medications, but where those medications are not effective by themselves.
This type of therapy, however, often results in the disadvantages of weight
gain and hypoglycemia.
Other treatment alternatives include the use of continuous subcutaneous
insulin infusion, and intraperitoneal systems. Still other treatment
regimens include inhalation and buccal insulin preparations. However, all of
the above therapies have disadvantages. The medications, for instance, which
force the pancreas to make still more insulin have the risk of accelerating
breakdown of the entire insulin regulatory system. Other side effects are of
Hence, it would be desirable to have an insulin control treatment that is
effective for a wide range of patients, yet have few or no side effects.
SUMMARY OF THE INVENTION
Accordingly, the present invention is an insulin and glucose control
formulation, comprising: methylhydroxychalcone polymer (MHCP); and chromium,
in therapeutically effective amounts, respectively.
BEST MODE FOR CARRYING OUT THE INVENTION
As discussed above, treatment for diabetes by improving insulin
sensitivity is typically divided between life style changes on the other
hand, and drug therapy on the other hand, although both types of treatment
have been used together. In the present invention, however, nutritional
therapy is used to produce a third treatment alternative which has been
found to slow the decline to final stage type 2 diabetes. The present
invention involves a new formulation that mimics the effect of insulin in
the human body, specifically a combination of 1) methylhydroxychalcone
polymer (MHCP) a compound found in cinnamon and 2)chromium. Other nutrients
can be added to this combination, as discussed in more detail below. The
formulation is prepared for ingestion in oral form.
MHCP is one part of the present formulation. It has been discovered that the
nutrient MHCP can stimulate glucose uptake by body cells, and even in some
cases assisting in the synthesis of glycogen, which is a polymer of glucose
produced by the body to store energy. When needed, such as during exercise,
glycogen is depolymerized back to glucose. Most gylcogen is found within the
liver but also in some muscles where it is mobilized when quick energy is
needed. MHCP helps in this synthesis production of glycogen.
Both of the above characteristics are insulin-related fuctions that help
maintain healthy blood sugar levels. MHCP has similar effects to insulin in
that it chemically modifies the individual cells' insulin receptors in such
a way to permit glucose molecules to pass through the cell wall into the
interior of the cell, where the glucose is used for energy production. The
series of molecular events initiated by insulin's interaction with its
receptor, known as insulin cascade, is also initiated or triggered by MHCP.
MHCP also has a synergistic effect on the insulin already present in the
body. MCHP thus has its own separate effect relative to type 2 diabetes but
also enhances the body's own insulin.
The amount of MHCP in the present formulation is in the range of 6-24
milligrams (mg) as a daily dose for effective therapeutic results.
In addition to its effect on insulin control relative to diabetes discussed
above, MHCP has been found to reduce blood pressure and also to reduce or
prevent the formation of oxygen radicals, an antioxidant effect, which has
been shown independently to reduce the progression of various complications
The other part of the present formulation is chromium, which is known to
improve blood sugar regulation by itself for type 2 diabetes. In the present
formulation, 500 to 2000 micrograms (mcg) of chromium in a daily dose has an
effective therapeutic effect, with 1000 mcgs (1 milligram) being preferred.
The combination of MHCP, in an amount in the range of 6-24 mg and chromium
in an amount in the range of 500 to 2000 mcgs, as a daily dose, produces a
therapeutic effect relative to delaying the onset and retarding the
progression of type 2 diabetes. The two elements are combined together in an
As indicated above, additional nutrients can be added to the above
combination to further enhance the insulin control effect. In one instance,
green tea extract, specifically polyphenols EGCG, enhance the operation of
insulin in the body. The green tea polyphenols are powerful natural
phytochemical antioxidants, and act as scavengers of free radicals. They
also chelate transition metal free radical catalysts such as iron. The
therapeutically effective amount of ECGC in the present formulation is
Other nutrients, which can be added to the formulation include various
vitamins, including vitamin B6, vitamin C, vitamin E and vitamin
K. In one embodiment, 10 mg of vitamin B6 is used, 200 mg of
vitamin C, 90 mcg of vitamin K and vitamin E 100 IU.
Additional ingredients include alpha-lipoic acid (an antioxidant) goat's rue
(galega officinalis, an herbal extract), quercetin (a favonoid), N-acetylcysteine
(an amino acid derivative) and the mineral vanadium. One embodiment includes
600 mg of alpha lipoic acid, 20 mg of goat's rue, 75 mg of N-acetylcysteine,
75 mg of quercetin and 1 mg of vanadium.
While the above additional nutrients promote, in one way or another, healthy
blood sugar levels, they are in addition to the basic formulation of the
present invention which comprises MHCP and chromium. In addition, the
amounts of the nutrients specified above may vary.
Hence, the present invention is a new formulation of MHCP and chromium, in
the therapeutically effective amounts set forth above, which aids in the
control of insulin and glucose, and more specifically is useful in the
treatment of or to prevent the onset of type 2 diabetes.
Claim 1 of 6 Claims
1. An insulin and glucose control daily dose formulation for treatment of
methylhydroxychalcone polymer (MHCP) in an amount within the range of 6-24
chromium, in an amount within the range of 500-2000 mcgs, wherein the
amount of MHCP and the amount of chromium are in combination
If you want to learn more
about this patent, please go directly to the U.S.
Patent and Trademark Office Web site to access the full